Single-injection products will drive the US Hyaluronic Acid Viscosupplementation market to nearly $1 billion by 2013, according to Millennium Research Group
WALTHAM, Mass., March 23 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Orthopedic Biomaterials 2009 report, the US launch of Genzyme Biosurgery's single-injection Synvisc-One will drive procedural growth in the hyaluronic acid (HA) viscosupplementation market. Released to the market in February 2009, Synvisc-One adoption will fuel HA viscosupplementation revenues to reach nearly $1 billion by 2013.
Prior to the launch, HA viscosupplementation treatments were available only in 3-and 5-injection regimens. Over the next several years, many physicians are expected to adopt single-injection products in place of the 3- and 5-injection treatments. Single-injection treatments, which offer greater convenience and less pain, will gain popularity among both patients and physicians over the next five years and will account for approximately one-third of treatments by 2013. With Synvisc-One currently the only approved single-injection treatment, Genzyme Biosurgery is positioned to benefit from this shift in preference.
"The HA viscosupplementation market is the fastest-growing segment of the orthopedic biomaterial market, fueled in particular by the rise of single-injection treatments," says Kevin Flewwelling, Manager of the Orthopedics division at MRG. "Now that Synvisc-One has approval in the US, the door is open for the release of other single-injection products that will be launched through to 2013, driving the high growth in this market."
In addition to HA viscosupplementation, MRG's US Markets for Orthopedic Biomaterials 2009 report covers bone graft substitutes, machined bone interbody devices, cell concentration systems, and knee cartilage repair. The report also provides coverage of all key industry competitors, including AlloSource, Biomet, Blackstone Medical (Orthofix), DePuy, Exactech, Ferring Pharmaceuticals, Genzyme Biosurgery, Integra LifeSciences, LifeNet Health, Medtronic Spinal and Biologics, Musculoskeletal Transplant Foundation, Orthovita, Osiris Therapeutics, Osteotech, RTI Biologics, sanofi-aventis, Smith & Nephew, Stryker, Synthes, Wright Medical Technology, and many more. Other reports in this series cover Europe and Asia Pacific.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized solutions.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Amy Krohn Millennium Research Group 416-364-7776 x101 firstname.lastname@example.org Elizabeth Marshall Decision Resources Inc. 781-296-2563 email@example.com
|SOURCE Millennium Research Group|
Copyright©2009 PR Newswire.
All rights reserved